Tags:BrandDevelopmentHealthInformationMedicalMedTechPharmacyProductSpecialtyWellness
Zecuity® transdermal patch to treat migraine headaches approved by the FDA in 2013. IPO (NASDAQ: PATH) completed in August 2010 and the company was acquired by Teva Pharmaceutical Industries Ltd. in February 2014. Exited Portfolio Company www.nupathe.com
Total raised: $28M

Investors 3

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
26.09.2012-$28M--

Mentions in press and media 11

DateTitleDescriptionCategoryAuthorSource
17.01.2013NuPathe ge...The approval for the Zecuity c...--medcitynew...
09.10.2012Migraine p...Anido replaced Jane Hollingswo...--medcitynew...
26.09.2012Migraine p...Armando Anido, the CEO of the ...--medcitynew...
26.09.2012Abiomed: M...Abiomed (NSDQ:ABMD) said it do...-MassDevice...massdevice...
26.07.2012Migraine p...“My number one priority is cas...--medcitynew...
25.07.2012Biopharmac...Incoming CEO and board member ...--medcitynew...
16.07.2012Migraine p...Jane Hollingsworth, NuPathe’s ...--medcitynew...
19.12.2011NuPathe CE...Six years after NuPathe’s laun...--medcitynew...
29.11.2011NB Therape...Iontophoresis involves using e...--medcitynew...
15.11.2011NuPathe to...Migraine headaches affect abou...--medcitynew...
Show more